CGRP mAb Subcutaneous denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Medical-Necessity Denial for Your CGRP Monoclonal Antibody

A medical-necessity denial from Cigna means the plan determined that the clinical evidence in the submitted prior-authorization request did not meet the criteria outlined in Cigna's coverage policy for CGRP monoclonal antibodies. This is the most common denial type for this drug class and almost always stems from incomplete documentation rather than a patient who genuinely does not qualify. Common documentation gaps include: missing headache frequency or severity records, no documented trial of required preventive medications, an incomplete prescriber letter, or chart notes that do not clearly link the diagnosis to functional impairment.

## Why This Denial Is Appealable

Cigna's medical-necessity criteria for CGRP antibodies are specifically written to match what neurologists and headache specialists document in routine clinical practice. When the chart is complete, the criteria are typically met. Because the denial is almost always documentation-driven, gathering the missing records and submitting a structured appeal is highly effective.

## Your Federal Appeal Rights

• ERISA §503 (self-funded employer plans) and state insurance regulations (fully insured plans) both guarantee a full-and-fair internal appeal with a written decision.
• ACA §2719 external review is available after final internal denial; the window is generally approximately four months.
• If migraines are causing rapid functional decline, hospitalization risk, or medication-overuse escalation, ask your prescriber to flag the appeal as expedited (decision typically required within 72 hours under federal rules).

## Documentation to Gather

• Diagnosis and severity confirmation: headache diary or chart-documented frequency and severity records; ICD-10 code; functional-impairment notes (missed work, ER visits, disability).
• Prior preventive treatment history: a dated, outcome-annotated list of each preventive medication tried — drug name, dates, dose range, reason for discontinuation (inadequate response, intolerance, contraindication). Obtain pharmacy records to corroborate dates.
• Prescriber medical-necessity letter: should state the diagnosis, summarize the failed preventive history, explain why this specific CGRP antibody is the appropriate next step, and reference the applicable guideline organization.
• Cigna's coverage policy: download the current CGRP medical coverage policy from cigna.com; your prescriber's letter and your documentation should address each criterion in order.

## Criteria-Mapping Structure

The most persuasive appeal format maps each Cigna policy criterion to a specific chart fact:

| Cigna Policy Criterion | Your Chart Evidence | |---|---| | Diagnosis of episodic or chronic migraine | Chart note date, ICD code, headache diary | | Adequate trial of required oral preventives (with dates and outcomes) | Pharmacy printout + visit note per agent | | Clinical severity / functional impairment | Disability days, ER visits, MIDAS or HIT-6 scores if documented | | Prescribing physician specialty | NPI profile, board certification if applicable |

Verify the exact eligibility thresholds and required prior-treatment steps by reading Cigna's current published policy and the FDA-approved prescribing label before submitting.